- Have any questions?
- +88-01714063309
- info@bdix.net
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial (The Lancet)
২০২০-২১ অর্থবছরে পরিচালন ও উন্নয়ন বাজেটের ভ্রমণ ব্যয় হ্রাসকরণ।
July 19, 2020Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (The Lancet)
July 20, 2020The Lancet
July 20, 2020
Feng-Cai Zhu, MSc, Prof Xu-Hua Guan, PhD, Prof Yu-Hua Li, PhD, Prof Jian-Ying Huang, MD, Prof Tao Jiang, PhD, Prof Li-Hua Hou, PhD, et al.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than million cases of COVID-19 worldwide, resulting in 551 000 deaths and severe economic disruption. After the initial outbreak, with more than 80 000 cases and 3000 deaths in China, COVID-19 has now spread to 216 countries and territories. Large numbers of cases and deaths are reported daily from Europe, the USA, Brazil, Russia, India, and many other countries.The current pandemic has highlighted the need for effective preventive solutions to reduce burden and spread of the disease. As long as there is a COVID-19 epidemic in one area in the world, there is a risk of a pandemic.